皆様方の治療に当たるスタッフ全員でご相談やご質問に答えるべく日夜新しい知識を身につけるよう精進しております。

１）Park Side Luncheon Seminar

毎週火曜日、金曜日を中心にクリニックにおいて、当院スタッフを対象に約３０−６０分の教育、勉強会を重ねております。内容については、後日まとめて紹介したく存じます。

10/2  動脈硬化；血管の固さとは？

9/29

9/15

9/8　下肢静脈瘤に対する硬化術治療

9/1　アレルギー総論

8/10-25 　一時中断

8/7　下肢静脈瘤に対する弾性ストッキング治療

8/4　高血圧治療の利尿剤の役割

7/31　糖尿病に対するインスリン治療の考え方

7/28　狭心症治療、亜硝酸の使い方

7/24　血管内皮機能について、動脈硬化の進展とは？

7/14　高齢者に対する高血圧症治療

7/7　高血圧基礎治療

6/　手洗い講習会

2)Park Side Evening Seminar

勤務している医師にそれぞれの専門の観点からスタッフ教育をお願いしています。

院長の基礎研究や臨床研究の成果などもスタッフ全員に浸透させる予定です。

1)Development of Novel DDS in Gene and Cell Therapies for Cardiocvascular Disease

Shin-Ichiro Yokoyama

Novel therapeutic strategies such as gene and cell therapies are going to be applied to treat severe diseases that cannot be improved with present medicines. Drug-eluting stents (DES) with nucleic acid medicines have been developed for the in-stent restenosis of coronary artery as a second-generation DES. In the trials of gene and cell therapies for severe ischemic heart disease and heart failure, development of safe and easy strategies are required to ensure the delivery of genes and cells into the heart. We address the above-mentioned issues using our recent studies. (J Jpn Coll Angiol, 2005, 45: 179–186)

A strategy of retrograde injection of bone marrow mononuclear cells into the myocardium for the treatment of ischemic heart disease.

Shin-Ichiro Yokoyama

OBJECTIVE: Bone marrow cells implantation (BMI) has been reported to efficiently improve ischemic heart disease. However, BMI strategies are generally invasive. To establish a BMI strategy for ischemic heart disease, we performed implantation of autologous cryopreserved mononuclear cells (MNCs) from bone marrow (BM) retrogradely into the myocardium via the coronary vein in pigs with acute myocardial infarction (AMI) and old myocardial infarction (OMI). METHODS: BM cells were harvested from the pigs’ fumurs. MNCs were collected by centrifugation and were cryopreserved. Anterior myocardial infarction was induced by occlusion of the midportion of the left anterior descending coronary artery without surgical intervention. Frozen BM cells were quickly thawed and injected retrogradely via the coronary vein into the myocardium through a single balloon infusion catheter 6 h and 2 weeks after the induction of infarction. Four weeks after implantation, coronary arteriograms were obtained, cardiac function was analyzed with the use of a conductance catheter, and histopathologic analysis was performed with a confocal laser microscope. Plasma levels of natriuretic peptides and angiogenic growth factors were measured after BMI. RESULTS: Flow cytometric analysis revealed that 90% of cryopreserved BM cells were viable in vitro. Labeled BM cells were entirely distributed around in the infarcted area of maycardium in pigs. BMI increased collateral neovascuralization in infarcted hearts. BMI significantly improved cardiac function in AMI with BMI and OMI with BMI groups. BMI also increased the formation of microcapillary arteries in infarcted hearts. Levels of natriuretic peptides were significantly decreased, and levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF2) were significantly increased after BMI. Confocal laser microscopy revealed the presence of proliferative and activated myocardial cells in infarcted hearts after BMI. CONCLUSION: The retrograde infusion of cryopreserved BM cells into myocardium efficiently induced angiogenesis and improved cardiac function in pigs with AMI or OMI. These results suggest that the present strategy of BMI will be safe and feasible as an angiogenic cell therapy for ischemic heart disease.　(J Mol Cell Cardiol. 2006 Jan;40(1):24-34. Epub 2005 Nov 4)